A recent study by Joshua Carmichael suggests that some earthquakes and seismic events might conceal underground nuclear tests ...

The following is a summary of “Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients ...

In the first long-term study of intraarterial peptide receptor radionuclide therapy (PRRT) in advanced meningioma, patients saw improved radiologic and clinical disease control compared with ...

Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® ...

In an interview with ThePrint, physicist Yogendra Narain Srivastava discusses his radical new theory of black holes and a ...

Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy ...

Scientists in the United States have stated that it might be possible for countries to hide their underground nuclear test explosions in the garb of seismic tremors generated by earthquakes. The ...

The study in India, has been approved to treat ... Building on the FDA “Breakthrough Device” status of Radiogel® Precision Radionuclide Therapy™, Vivos is sharing preliminary India trial ...

Could the seismic signal of an underground nuclear test explosion be 'hidden' by the signal generated by a natural earthquake?

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo ...

EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...